Hydroxychloroquine takes another hit in failed small-scale COVID-19 study
Despite President Donald Trump's backing, hydroxychloroquine has shown mixed results in treating COVID-19. (Pixabay)
Antimalarial hydroxychloroquine has raked in support as a potential wonder drug to treat COVID-19, with even President Donald Trump touting it as a possible "game changer." But small-scale studies have been less than definitive on the drug's chances—and new data haven't cleared matters up much.
A U.S. Department of Veterans Affairs (VA) study (PDF) found that severe COVID-19 patients treated with antimalarial hydroxychloroquine alone or in combination with antibiotic azithromycin showed "no evidence" of reduced risk of death or mechanical ventilation over supportive care, according to data posted Tuesday.
In a small-scale analysis of 368 COVID-19 patients treated in VA hospitals, researchers found there was no significant difference in ventilation risk for all three cohorts. Meanwhile, patients treated with hydroxychloroquine alone showed a significantly higher risk of all-cause mortality over either supportive care of a combination of hydroxychloroquine and azithromycin.
What could you do with real-time supply chain information at your fingertips?
Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!
The researchers noted their analysis was not randomized nor controlled and cautioned patience for several ongoing clinical studies to read out before drawing conclusions on hydroxychloroquine's use for COVID-19.